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Human insulin degrading enzyme (IDE) plays a role in the proteolytic 
cleavage of insulin, glucagon, and other short, hydrophobic peptides with 
roles in glucose and cellular metabolism. Because of IDE’s role in insulin 
clearance, IDE inhibitors may hold promise as therapies for potentiating 
insulin signaling in patients suffering from type 2 diabetes mellitus. IDE is 
a large (~100 kDa) chambered protease of the conserved M16A 
subfamily of zinc metalloproteases. The enzyme adopts a structure that 
is analogous to a clamshell formed by the joining of the N terminal and C 
terminal domains. The characteristic zinc binding and catalytic motif 
(HXXEH) is positioned within the enzyme’s N terminus, while C terminal 
residues also play important roles in substrate binding and catalysis. 
Here, we describe the use of a computational work-flow for identifying 
novel IDE inhibitors. The work flow integrates mutation-based active site 
structural analysis, virtual screening, docking and fragment-based 
design. Initial computational results appear promising and should lead to 
assay testing in the near future. Trends in Endocrinology & Metabolism 2016 27, 24-34DOI: 
(10.1016/j.tem.2015.11.003,
v Two key conformational 
switches open and closed 
transition in absence of 
substrate
v Partly open allow smaller 
substrates peptides  
(bradykinin) fully open larger 
substrates such as insulin
v Dimeric IDE structure. The 
key features of IDE including 
IDE-N, IDE-C, catalytic zinc 
ion, and door subdomain, are 
colored in cyan, green, gray, 
and red, respectively, while 
the surface of catalytic 
chamber of IDE is in gray
Leissring,J. Med. Chem., 2013, 56 (6), pp 2246–2255, Nat Commun. 2015 Sep 23;6:8250, J Biol Chem. 2015 Aug 
14;290(33):20044-59, Eur J Med Chem. 2015 January 27; 90: 547–567, Nature volume 511, pages 94–98 (03 July 2014)
.
v Known 60 nM inhibitor crystal structure used
v Forms close contacts at catalytic site with IDE-N, IDE-C
v Chelates to zinc ion with hydroxamate
v Fluorine group form π stacking interaction with Phe820 
v Triazole interacts with Arg824  
v Naphthyl group hydrophobic interactions F820, F834
Nature 
Communication
s volume 6, 
Article number: 
8250 (2015)
doi:10.1038/nc
omms9250
Protein-Receptor
Virtual Libraries based 
on physical properties 
from Zinc Database
Predicted ligand poses 
and binding affinities 
rescoring using four other 
criteria 
Docking 
Software 
Vega-ZZ
v Generates poses and ΔG’s
v Each virtual compound has ten different poses
v Sort out duplicates between the five different binding criteria
v Compare pose to crystal ligand pose
v Analyze distance of docked ligand and metal in enzyme 
v Look for hydrogen bonding interactions
v Analyze fit in binding pockets look for cavities in enzyme
v Look for acceptable pose buy compound test on in vitro assay
v Generate pharmacological hit 
J. Chem. Inf. Model., 2015, 55 (11), pp 2324–2337
v Rationally design virtual library based on Lipinski’s Rules
molecular weight, log P, and other criteria
v Test only compounds that can be purchased with the
selected compounds to be  tested on just the
target/enzyme
v When pharmaceutical hit is found it  can be drawn to find 
congeners for further optimization
v Top 5% of virtual 
compounds are 
summarized in excel 
sheet
v Each virtual compound 
10 different 
conformations
v Excel computes 
duplicates from the five 
different criteria that 
evaluates virtual 
docking studies
v Insulin-degrading enzyme (IDE)  a 110 kDa zinc metalloprotease is 
involved in the clearance of many bioactive peptide substrates, 
including insulin (Km = 85 nM) and amyloid-beta, peptides vital to the 
development of diabetes and Alzheimer's disease, respectively
v Located in the cytosol its proteolytic activity subject to complicated 
signaling regulation inside of cells
v The role of IDE in the clearance of insulin suggests that IDE       
inhibitors could be used moderate levels of insulin in type 2 patients
v The IDE active site consists of two clamshell like structure 
connected by a liker which is flexible allowing “open and closed 
state” which allows access to the catalytic zinc
v Large active site called crypt ~ 15,700  Å
v IDE can exist in solution as monomer and then aggregates to its 
most active form the dimer
v When the enzyme opens the enzyme encapsulates the substrate 
that primarily bind to an exosite 30 Å away
J. Mol. Biol. 395, 430-443 (2010), J Biol Chem. 2015 Aug 14;290(33):20044-59, Trends in Endocrinology & 
Metabolism 2016 27, 24-34DOI: (10.1016/j.tem.2015.11.003, Eur J Med Chem. 2015 January 27; 90: 547–567
v Using physical properties for the ligands, multiple parameters for  
docking studies allows smaller more manageable libraries/ data
v Biological assay/testing of the interesting compounds from docking 
studies to be evaluated  in vitro on the target enzyme
v Initial identification of the pharmaceutical hit optimize via virtual 
compounds
v Identification of the pharmacophore
v Site directed mutagenesis studies  
v Looking for biological clues that will drive the synthetic chemistry
v Are there cavities in the enzyme that can be build into
v Find new hydrogen bonding interactions
v Fragment based drug design
v Generate synthetic schemes to generate congeners of the  
pharmaceutical hit
v Continue molecular modeling to support synthetic chemistry 
v Evaluate pharmacokinetics  ADME
Table 1 Different parameters 
applied for the docking studies
Figure 2  Pose of both docked 
ligand and crystal structure 
inhibitor (gold) from protein 
model 
Figure 1 Pose of docked ligand 
showing the distance with the metal 
zinc (green) look for distances < 2.5 Å
Figure 3 Pose of docked potential 
inhibitor with crystal structure 
ligand(gold), metal zinc (green) Figure 4  IDE inhibitor at active site 
gray hydrophobic area
Figure 5 Pose of docked potential 
inhibitor at the binding pocket showing 
cavities
Figure 6  IDE inhibitor (white) at active site showing potential hydrogen 
bonding with SER 138, amino acids: shades of blue non-polar, green 
polar, brown charged.
v Active site of IDE 
very large 15,700  
Å cavities to build 
into
v Generate virtual 
compound library 
of congeners of 
known IDE 
inhibitors 
v Generate virtual 
compound library 
of higher 
molecular weights
Potential IDE inhibitor 
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